NVO
Meme
Social trend and summarized meme
$85.00
-20.52% weekly
-17.83%
Last Hour Posts
+50.0%
2
Last 24hrs Posts
-13.8%
16
1hr Avg Sentiment
-100.0%
0.0000
24hrs Avg Sentiment
+150.7%
0.1672
Inst Hold: 8.6%
Short Pct: %
Sentiment vs. Performance
Updated 2024-12-23T09:38:36+00:00 browser time.
*
R500 ranks any stock, ETF, mutual fund, plus some crypto against all SP500 component stocks,
over a period of time, refreshed every 10 minutes.
The lower the R500 the better.
By default, R500 ranks over the latest trading day.
** Sum of post sentiment times post up votes
Rank NVO
Eli Lilly got their weight-loss drug approved for sleep apnea as well. ONE DAY after $NVO shit the bed on theirs.
Posted 2024-12-21T21:53:33, updated 2024-12-21T22:30:20 20 -0.8081 wallstreetbets
The NVO a combo drug saw people losing fucking 23% of their body weight. That's insane. They missed their 25% target. The issue is their target, not that the drug doesn't work well.
Most recent 2024-12-23T00:33:35+00:00
Eli Lilly got their weight-loss drug approved for sleep apnea as well. ONE DAY after $NVO shit the bed on theirs. 1 0.598 wallstreetbets
Dose doesn't correlate like that across molecules. And not titrating to max dose because "they were ...
- And not titrating to max dose because "they were satisfied with their weight loss" is a hilarious way to look at it when it's well known all GLP's suffer from significant tolerability challenges with higher doses.
- It's a big enough market that there will be multiple winners.
1 day ago 2024-12-22T04:18:05+00:00
Eli Lilly got their weight-loss drug approved for sleep apnea as well. ONE DAY after $NVO shit the bed on theirs. 4 -0.7778 wallstreetbets
Dude, NVO. I bought at the top, betting with fat Americans, but even a 60 Minutes segment did not i...
- I bought at the top, betting with fat Americans, but even a 60 Minutes segment did not increase the stock price the next day.
- The 60 Minutes piece did have company representatives basically say money is not their first priority.
- Basically, poison to capitalist pigs.
NVO price action is concerning 1 0.8858 stocks
The European piece is actually massive challenge that cannot be overlooked. Only the US market allow...
- Only the US market allows its citizens to be a captive atm machine to the pharmaceutical racket, and 60% of NVO's profits are from that market last I checked 2 months back.
- With an official policy of 'America First' and an unofficial 'quid pro quo' with companies lining the Trump family pockets, it may be difficult for NVO to compete.
- China and India simply cannot enforce ripoff generic restrictions and will not be able to make up for lost US revenue.
- I still think it's a bargain at these prices, but not fighting on a fair playing field anymore in its most important market.
NVO price action is concerning 1 0.7964 stocks
I still think it's a long term hold. I've been watching NVO for a while, even opened a virtual posit...
- I've been watching NVO for a while, even opened a virtual position on it earlier this year.
- But after Friday's 20% plummet, I opened an actual position.
- I think it's a good time to get into it and for people like you to average your price down.
Weekend Discussion Thread for the Weekend of December 20, 2024 1 -0.5677 wallstreetbets
I'm concerned this sell off in NVO could have a systemic impact on the Danish economy, with Danske b...
- I'm concerned this sell off in NVO could have a systemic impact on the Danish economy, with Danske bank saying recently it contributed to half of Denmarks GDP growth this year.
- The Krone got hit as well, if their central bank has to raise rates to defend it then look out below.
- Finnish GDP basically never recovered from the GFC, which coincided with Nokia's decline.
- Now it's a question of whether Ozempic and Cargisema are to Tirzepatide and Retatrutide what the Nokia N95 was to the iPhone.
- The N95 outsold the iPhone for 3 quarters by the way, so Ozempic being the king in this space still doesn't say much.
2 days ago 2024-12-21T00:44:27+00:00
Novo Nordisk experienced the most insane one-day movement, seemingly based on nothing. 122 -0.913 wallstreetbets
NVO bears r fukt. The 22.7% weight loss wasn't even with everyone on max dose - [only 57.3% of patie...
- The 22.7% weight loss wasn't even with everyone on max dose - [only 57.3% of patients actually took the high dose](https://finance.yahoo.com/m/85b1f6f8-2bf0-3e20-892a-cf73eeae8ce5/novo-nordisk-stock-crashes-on.html).
- Market overreacted hard.
- [LLY already prints money](https://beyondspx.com/article/eli-lilly-lly-a-diversified-pharmaceutical-powerhouse-poised-for-sustained-growth) with Mounjaro ($8.01B in first 9 months) but NVO's gonna keep eating too.
- Fat people aren't going anywhere lmao.
- Obesity market too thicc to fail.
NVO price action is concerning 13 0.9752 stocks
I monitor both LLY and NVO since the day I know about these two companies. Whenever they are down, I...
- Do not see price action, if you invest these companies, just buy them when they are crashed like today.
- In fact, I purchased pre-market and market hours NVOX (2x of NVO) as I expect them to recover.
- Reason: The drug test proved 22% weight reduction success while market is expecting 25%.
- Don't you think it is silly issue as NVO can capture the market with price competitiveness.
- Any way, any drop in price, in good companies, are opportunity to buy more.
Eli Lilly got their weight-loss drug approved for sleep apnea as well. ONE DAY after $NVO shit the bed on theirs. 20 -0.8081 wallstreetbets
The NVO a combo drug saw people losing fucking 23% of their body weight. That's insane. They missed ...
NVO price action is concerning 2 0.9766 stocks
Food for thought: LLY's next drug retatrutide is performing very well in trials, whilst NVO's hopefu...
- Food for thought: LLY's next drug retatrutide is performing very well in trials, whilst NVO's hopeful competitor, CagriSema, just had a moderate underperformance vs expectation in trials.
- Mounjaro/zepbound is already the better drug than ozempic/wegovy, and LLY seems to be securing the same dynamic for the next generation.
- The brand name of "ozempic" has carried NVO far, even while a better drug was available (mounjaro).
- They're losing the efficacy battle and their branding superiority is about to be moot with the next generation.
- LLY is the easy favorite in the obesity business.
2 days ago 2024-12-20T12:55:05+00:00
Eli Lilly (LLY) or Novo Nordisk (NVO)? 3 -0.6808 stocks
NVO is taking a beating today on the stock market. The test results on the new drug are disappointin...
Daily Discussion Thread for December 20, 2024 2 -0.8565 wallstreetbets
A very Grinch Christmas this year!  Fuck it,...
- NVO meltdown in particular is absolutely ridiculous and not justified at all.
r/Stocks Daily Discussion & Fundamentals Friday Dec 20, 2024 1 0.9777 stocks
Hahah totally. I'm also west coast, but I'm naturally up like 5AM every day. Kind of cool, kind of s...
- There's like one other time that I've done something like that, which was like a few quarters ago when DDOG dropped off an ok report in the pre-market.
- I did it this morning with NVO, hoping I didn't catch a failing knife.
6 days ago 2024-12-17T06:00:40+00:00
Eli Lilly (LLY) or Novo Nordisk (NVO)? 2 0.956 stocks
I recently started investing in both companies. I'm 90% weighted towards NVO and 10% weighted toward...
- Even if Mounjaro and Zepbound are better than Wegovy and Ozempic, I think NVO will be fine.
- The company overall has such an impressive balance sheet and performs so well financially in every aspect.
- I don't suspect the growth will stop if LLY's new round of medication is better.
- I think the growth will slow, but NVO will get back on track and make a better drug in the near future.
- For now, I'm dollar cost averaging into both companies at a 90/10 NVO to LLY ratio.
Day-by-day Polarity
| Date** | Open | High | Low | Close or Current | R500* | Mentions | Positive Mentions | Up Votes | Voted Sentiment** |
|---|---|---|---|---|---|---|---|---|---|
| Mon 2024/12/23 | 5 | 3 | 5 | -0.11 | |||||
| Sun 2024/12/22 | 13 | 11 | 16 | 0.05 | |||||
| Sat 2024/12/21 | 15 | 10 | 171 | -109.34 | |||||
| Fri 2024/12/20 | -20.03% | -16.35% | -21.21% | -17.83% $85.00 | #501 | 89 | 59 | 125 | -3.11 |
| Thu 2024/12/19 | -1.59% | -1.14% | -3.04% | -2.38% $103.44 | #467 | 1 | 0 | 2 | -1.44 |
| Wed 2024/12/18 | +0.35% | +0.95% | -2.34% | -1.90% $105.96 | #121 | 1 | 1 | 1 | 0.43 |
| Tue 2024/12/17 | -0.28% | +0.87% | -0.30% | -0.04% $108.01 | #133 | 3 | 3 | 4 | 2.66 |
| Mon 2024/12/16 | +2.19% | +2.74% | +0.86% | +1.03% $108.05 | #51 | 1 | 1 | 1 | 0.30 |
| Sun 2024/12/15 | 2 | 0 | 3 | -1.54 | |||||
| Sat 2024/12/14 | 1 | 0 | 1 | -0.25 | |||||
| Fri 2024/12/13 | -1.45% | -0.92% | -4.12% | -1.53% $106.95 | #441 | None | 0 | None | |
| Thu 2024/12/12 | -0.73% | -0.47% | -2.94% | -2.76% $108.61 | #484 | None | 0 | None | |
| Wed 2024/12/11 | +1.15% | +3.05% | +0.76% | +2.29% $111.69 | #32 | None | 0 | None | |
| Tue 2024/12/10 | +0.42% | +0.42% | -2.14% | -1.70% $109.19 | #412 | None | 0 | None | |
| Mon 2024/12/09 | +0.86% | +1.10% | -0.42% | +0.28% $111.08 | #193 | None | 0 | None | |
| Fri 2024/12/06 | +1.02% | +2.29% | +0.85% | +1.79% $110.77 | #31 | None | 0 | None | |
| Thu 2024/12/05 | -0.32% | +0.32% | -0.68% | -0.14% $108.82 | #208 | None | 0 | None | |
| Wed 2024/12/04 | +0.93% | +1.21% | -0.22% | -0.21% $108.97 | #271 | None | 0 | None | |
| Tue 2024/12/03 | +1.94% | +2.03% | +0.35% | +0.49% $109.20 | #74 | None | 0 | None | |
| Mon 2024/12/02 | +1.99% | +2.19% | +1.26% | +1.75% $108.67 | #45 | None | 0 | None | |
| Fri 2024/11/29 | -0.66% | +1.20% | -0.73% | +0.63% $106.80 | #145 | None | 0 | None | |
| Wed 2024/11/27 | % | % | % | +0.00% $106.13 | #270 | None | 0 | None | |
| Tue 2024/11/26 | +2.02% | +3.00% | +1.02% | +1.50% $106.13 | #53 | None | 0 | None | |
| Mon 2024/11/25 | +0.24% | +0.82% | -1.01% | -0.48% $104.56 | #430 | None | 0 | None | |
| Sat 2024/11/23 | 1 | 1 | 1 | 0.00 | |||||
| Fri 2024/11/22 | +1.25% | +3.52% | +1.20% | +2.37% $105.06 | #41 | 6 | 6 | 8 | 4.59 |
| Thu 2024/11/21 | -1.99% | -1.95% | -3.57% | -2.51% $102.63 | #499 | 2 | 0 | 2 | -1.24 |
| Wed 2024/11/20 | +0.78% | +3.03% | +0.36% | +2.57% $105.27 | #26 | 1 | 1 | 1 | 0.00 |
| Tue 2024/11/19 | +1.37% | +3.32% | +1.33% | +2.83% $102.63 | #9 | 8 | 5 | 14 | -0.65 |
| Mon 2024/11/18 | -1.40% | -0.73% | -2.28% | -1.90% $99.81 | #488 | 7 | 5 | 8 | 3.41 |
| Sun 2024/11/17 | 3 | 2 | 3 | -0.48 | |||||
| Sat 2024/11/16 | 2 | 1 | 2 | -0.34 | |||||
| Fri 2024/11/15 | -3.47% | -2.83% | -4.75% | -3.40% $101.74 | #449 | 1 | 1 | 1 | 0.41 |
| Thu 2024/11/14 | -0.07% | +0.08% | -1.79% | -1.49% $105.32 | #371 | 1 | 1 | 1 | 0.00 |
| Wed 2024/11/13 | -0.17% | +0.68% | -0.48% | -0.14% $106.91 | #287 | 1 | 1 | 1 | 0.00 |
| Tue 2024/11/12 | -2.09% | -1.36% | -3.11% | -1.86% $107.06 | #421 | 2 | 0 | 0 | 0.01 |
| Mon 2024/11/11 | +2.30% | +3.18% | +1.61% | +1.76% $109.09 | #107 | None | 0 | None | |
| Fri 2024/11/08 | -0.45% | +0.22% | -1.11% | -0.40% $107.20 | #366 | None | 0 | None | |
| Thu 2024/11/07 | +0.70% | +2.26% | +0.22% | +2.15% $107.63 | #62 | 1 | 1 | 1 | 0.00 |
| Wed 2024/11/06 | -1.69% | -1.25% | -4.63% | -4.33% $105.36 | #484 | 3 | 3 | 4 | 1.84 |
| Tue 2024/11/05 | -1.59% | +0.53% | -1.80% | +0.37% $110.13 | #405 | 6 | 6 | 7 | 2.39 |
| Mon 2024/11/04 | -1.56% | -1.14% | -2.23% | -1.98% $109.72 | #478 | 3 | 2 | 3 | -0.75 |
| Sun 2024/11/03 | 2 | 2 | 2 | 0.52 | |||||
| Sat 2024/11/02 | 1 | 1 | 1 | 0.00 | |||||
| Fri 2024/11/01 | +0.83% | +0.96% | -0.14% | -0.01% $111.94 | #253 | 9 | 7 | 22 | -5.88 |
| Thu 2024/10/31 | -2.68% | -0.95% | -3.19% | -1.14% $111.95 | #293 | 3 | 3 | 9 | 5.78 |
| Wed 2024/10/30 | -2.76% | +1.59% | -4.23% | +1.13% $113.24 | #70 | 3 | 2 | 18 | -7.17 |
| Tue 2024/10/29 | -0.66% | +0.81% | -1.08% | -0.34% $111.98 | #221 | 1 | 1 | 1 | 0.00 |
| Mon 2024/10/28 | -0.86% | -0.58% | -1.51% | -0.90% $112.36 | #455 | 1 | 1 | 1 | 0.42 |
| Sun 2024/10/27 | 1 | 1 | 7 | 6.57 | |||||
| Sat 2024/10/26 | 1 | 1 | 2 | 1.88 | |||||
| Fri 2024/10/25 | -0.02% | +0.24% | -0.72% | -0.47% $113.38 | #240 | 1 | 1 | 1 | 0.00 |
| Thu 2024/10/24 | -0.46% | -0.41% | -1.58% | -1.57% $113.92 | #455 | 3 | 2 | 4 | 1.79 |